BankingBusiness

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Previous article
Swift: Passes on €50 million one-time discount
Next article
Added Health: Raises Over £1M
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

FinTech

BMO Strengthens AI and Quantum Research with New Institute

The new institute will focus on advancing AI technology and quantum computing.Highlights: BMO launches Institute for AI and...
FinTech

Lloyds Strengthens Leadership with AI Agent in the Boardroom

The British bank integrates artificial intelligence into executive decision-making.Highlights: Lloyds Banking Group introduces an AI agent to its...
FinTech

Ralio Secures $25M to Strengthen Agentic Payments Platform

Funding aims to enhance features and expand market reach.Highlights: Ralio raises $25M in a funding round.The investment will...
FinTech

Regulators Brief Banks on Anthropic Cyber Risk Amid Growing Concerns

Regulatory bodies emphasize urgent risks from Anthropic's AI developments.Highlights: Regulators issue warnings about Anthropic's AI-related cyber risks.Financial institutions...